close
Add to watchlist
Hemispherx Biopharma, Inc (HEB) Healthcare, Biotechnology & Drugs
Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of new drug therapies for the treatment of viral and immune based chronic disorders. The company's products include Alferon N Injection for the treatment of genital warts; and Ampligen, an experimental drug that is in human clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, HIV, renal cell carcinoma, and malignant melanoma. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of viral diseases and disorders of the immune system. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.31 |
| Volume | 153996 |
| Volume Avg | 524429 |
| 52 Week High | 0.57 |
| 52 Week Low | 0.17 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.07 |
| EPS change Q/Q | -50% |
| EPS change Q/Q Yr ago | -75% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -57.14% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |